Compare iShares International Treasury Bond ETF (IGOV) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares International Treasury Bond ETF vs Natera Inc. Common Stock — how do they compare? iShares International Treasury Bond ETF trades at $39.67 (market cap $1.31B), while Natera Inc. Common Stock trades at $393.27 (market cap $57.03B). The key difference: Natera Inc. Common Stock is far larger — about 43.5× iShares International Treasury Bond ETF's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, iShares International Treasury Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares International Treasury Bond ETF for 92 Days and Natera Inc. Common Stock for 0 Days on average.
| IGOV | NTRA | |
|---|---|---|
Market Cap | $1.31B | $57.03B |
Volume | 98,249 | 1,131,157 |
Sector | Fixed Income | Health |
52-Week High | $42.99 | $425.64 |
52-Week Low | $39.58 | $179.42 |
Typical Hold Time | 92 Days | 0 Days |
Enterprise Value | — | $56.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IGOV trades at $39.67, showing modest daily gains of 0.23% amid bearish technical signals. The stock faces selling pressure with moving averages indicating a downtrend, though oscillators suggest potential near-term momentum. Recent news highlights rising global bond yields creating headwinds for financial markets, while the company's key financial ratios remain undisclosed in current data.
The outlook remains cautious with technical indicators favoring bearish sentiment. Investment opportunities depend on improved fundamental metrics and market stabilization, while risks include persistent bond yield pressures and lack of clear profitability data. Stock investors should await clearer financial performance indicators before establishing positions.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares International Treasury Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index and will invest at least 90% of its assets in fixed income securities included in the underlying index. The underlying index measures the performance of fixed-rate, local currency, investment-grade, sovereign bonds from certain developed markets. The fund is non-diversified.
Read more on IGOV →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
